NCT00672945终止2 期
Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 420
- 试验地点
- 38
- 主要终点
- Alzheimer's Disease Assessment Scale-Cognitive subscale.
研究概览
简要总结
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 in subjects with Alzheimer's Disease receiving a stable dose of donepezil. The study consists of a 26-week double-blind treatment period.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
PRX-03140
Experimental
干预措施: PRX-03140 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Alzheimer's Disease Assessment Scale-Cognitive subscale.
次要结局
未报告次要终点
研究者
研究点 (38)
Loading locations...
相似试验
终止
2 期
Study of PRX-03140 Monotherapy in Subjects With Alzheimer's DiseaseAlzheimer's DiseaseNCT00693004Epix Pharmaceuticals, Inc.236
已完成
2 期
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationAlzheimer DiseaseBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersMild Cognitive ImpairmentDementiaNCT05318976Inmune Bio, Inc.207
已完成
2 期
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT00889707Sophiris Bio Corp92
已完成
2 期
Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01254773JANSSEN Alzheimer Immunotherapy Research & Development, LLC146
终止
2 期
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On DonepezilAlzheimer's DiseaseNCT01712074Pfizer186